- Home
- AFCG vs PLX Comparison
AFCG vs PLX Comparison
Compare AFCG & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFCG
- PLX
- Stock Information
- Founded
- AFCG 2020
- PLX 1993
- Country
- AFCG United States
- PLX Israel
- Employees
- AFCG N/A
- PLX N/A
- Industry
- AFCG Real Estate Investment Trusts
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AFCG Real Estate
- PLX Health Care
- Exchange
- AFCG Nasdaq
- PLX Nasdaq
- Market Cap
- AFCG 189.9M
- PLX 160.2M
- IPO Year
- AFCG 2021
- PLX 1998
- Fundamental
- Price
- AFCG $7.91
- PLX $2.39
- Analyst Decision
- AFCG Buy
- PLX Strong Buy
- Analyst Count
- AFCG 6
- PLX 1
- Target Price
- AFCG $12.00
- PLX $15.00
- AVG Volume (30 Days)
- AFCG 112.5K
- PLX 634.9K
- Earning Date
- AFCG 03-13-2025
- PLX 03-13-2025
- Dividend Yield
- AFCG 18.29%
- PLX N/A
- EPS Growth
- AFCG N/A
- PLX N/A
- EPS
- AFCG 0.40
- PLX N/A
- Revenue
- AFCG $43,164,939.00
- PLX $45,667,000.00
- Revenue This Year
- AFCG N/A
- PLX N/A
- Revenue Next Year
- AFCG N/A
- PLX $63.84
- P/E Ratio
- AFCG $21.55
- PLX N/A
- Revenue Growth
- AFCG N/A
- PLX N/A
- 52 Week Low
- AFCG $7.45
- PLX $0.82
- 52 Week High
- AFCG $10.88
- PLX $2.76
- Technical
- Relative Strength Index (RSI)
- AFCG 31.84
- PLX 48.43
- Support Level
- AFCG $8.06
- PLX $2.43
- Resistance Level
- AFCG $8.88
- PLX $2.73
- Average True Range (ATR)
- AFCG 0.22
- PLX 0.13
- MACD
- AFCG -0.00
- PLX -0.04
- Stochastic Oscillator
- AFCG 10.19
- PLX 13.95
About AFCG AFC Gamma Inc.
Advanced Flower Capital Inc is a commercial mortgage REIT that provides institutional loans to state-law-compliant cannabis operators in the U.S. Through the management team's deep network and significant credit and cannabis expertise, AFC originates, structures and underwrites loans ranging from $10 million to over $100 million, typically secured by quality real estate assets, license value and cash flows.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.